Saturday 17 October 2026 Export RCUS’s income statement to Excel — free account

Arcus Biosciences, Inc.

Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024. In the quarter to June 2026, revenue fell 74.4%, EPS was flat, free cash flow grew 10.5% and total debt rose 4.12%, each against the same quarter a year earlier.

22.12 0.70 −3.07%

Follow RCUS

Alert me

Market cap: $2.9B
P/E: 0.0×
Fwd P/E: −6.3×
Dividend yield: —
F-score: 0/9
Altman Z: 1.11
Beneish M: −2.42
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.43

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	9	1	—	—	—	1	2	1	1	—	—

Insider Ownership 32.20%

Capital & Financial Ratios $m

Market Cap 2,910.00

Revenue 117.00

Net Income (460.00)

Free Cash Flow (474.00)

Net Debt (601.00)

Current Ratio 3.82

Debt/Equity 0.22

P/E ratio 0.00

Fwd P/E (6.31)

P/S ratio 23.84

P/B ratio 6.01

Past 5Y EPS Growth —

This Y EPS Growth (7.98%)

Next Y EPS Growth 7.23%

Next Y revenue growth (69.92%)

Next 5Y EPS Growth 8.30%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 61.44%

10-year low 10-year high

P/B against its own 10 years 92.55%

10-year low 10-year high

EV/Sales against its own 10 years 72.26%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	759	978	981	702
Receivables	38	20	11	36
Inventory	—	—	—	—
Other	—	—	—	—
	831	1,016	1,007	756

	2023	2024	2025	Q'26
Payables	17	18	42	34
ST’ Debt	—	—	—	—
Other	76	123	154	145
	184	226	231	198

Compound Annual Growth %

	10y	5y	3y
Sales	—	25.93%	30.16%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	4.67%	(1.34%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	17	41	—	—	—
’25	28	160	26	33	247
’24	145	39	48	26	258
’23	25	29	32	31	117
’22	18	27	33	34	112
’21	9	9	9	355	383
’20	2	2	65	10	78

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(138)	(119)	—	—	—
’25	(132)	(133)	(97)	(120)	(482)
’24	(2)	(94)	26	(100)	(170)
’23	(98)	(57)	(63)	(88)	(306)
’22	654	(65)	(81)	(70)	438
’21	(66)	(74)	(54)	(62)	(256)
’20	(31)	(24)	216	(50)	111

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(138)	(119)	—	—	—
’25	(133)	(133)	(97)	(121)	(484)
’24	(6)	(94)	25	(101)	(176)
’23	(101)	(62)	(73)	(94)	(330)
’22	651	(66)	(83)	(70)	432
’21	(70)	(80)	(62)	(70)	(282)
’20	(31)	(24)	215	(52)	108

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.02)	(0.72)	—	—	—
’25	(1.14)	0.00	(1.27)	(0.89)	(3.29)
’24	(0.05)	(1.02)	(1.00)	(1.03)	(3.14)
’23	(1.09)	(1.04)	(0.94)	(1.08)	(4.15)
’22	(0.96)	(0.93)	(0.90)	(0.93)	(3.71)
’21	(1.08)	(1.09)	(1.11)	3.71	0.71
’20	(0.63)	(0.93)	0.03	(0.82)	(2.24)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	9.17	6.30	8.55	22.36	16.74	12.95	13.52	6.50	Analyst estimates 2026–2028 Powerpack
	High	—	—	22.10	13.66	37.41	49.10	42.05	25.47	20.31	26.40
People
People	Employees	—	—	108	139	236	366	500	577	627	601
	Revenue/emp, $m	—	0.00	0.08	0.11	0.33	1.05	0.22	0.20	0.41	0.41
Income, $m
Income, $m	Revenue	—	1	8	15	78	383	112	117	258	247
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(18)	(53)	(50)	(85)	(123)	55	(266)	(301)	(282)	(353)
	EBT margin, %	0.00	(3,756.69)	(593.73)	(564.73)	(157.69)	14.36	(237.50)	(257.26)	(109.30)	(142.91)
	Net income	(18)	(53)	(50)	(85)	(123)	53	(267)	(307)	(283)	(353)
	Depreciation	1	3	2	1	3	9	6	(11)	(15)	(3)
Per share, $
Per share, $	Revenue	0.00	0.77	0.24	0.34	1.42	5.53	1.56	1.58	2.86	2.30
	Earnings	(20.80)	(29.04)	(1.43)	(1.93)	(2.24)	0.76	(3.71)	(4.15)	(3.14)	(3.29)
	Cash flow	(14.98)	(13.71)	(1.24)	(1.68)	2.03	(3.69)	6.08	(4.14)	(1.89)	(4.49)
	Capex	(4.74)	(3.02)	(0.11)	(0.04)	(0.05)	(0.38)	(0.08)	(0.32)	(0.07)	(0.02)
	Free cash flow	(19.73)	(16.72)	(1.35)	(1.72)	1.97	(4.07)	6.00	(4.46)	(1.95)	(4.51)
	Book value	0.00	84.17	6.79	3.74	9.17	12.15	9.13	6.24	5.38	5.88
	Shares, m	1	2	35	44	55	69	72	74	90	107
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	58.65	0.00	0.00	0.00	0.00
	P/S	—	0.00	44.64	29.51	18.24	7.32	12.99	12.45	5.20	10.36
	P/B	—	0.00	1.59	2.70	2.83	3.33	2.21	3.15	2.77	4.06
	EV/Sales	—	0.00	13.92	16.96	9.09	6.33	5.02	6.96	1.60	6.79
	EV/FCF	—	4.73	(2.49)	(3.37)	6.56	(8.59)	1.30	(2.47)	(2.34)	(3.47)
Cash, $m
Cash, $m	Operating cash flow	(13)	(25)	(43)	(73)	111	(256)	438	(306)	(170)	(482)
	Capex	(4)	(6)	(4)	(2)	(3)	(26)	(6)	(24)	(6)	(2)
	Free cash flow	(17)	(31)	(47)	(75)	108	(282)	432	(330)	(176)	(484)
Balance, $m
Balance, $m	Working capital	94	164	242	170	614	1,096	874	647	790	776
	Total debt	—	—	—	—	15	117	117	—	48	99
	Net debt	(99)	(176)	(257)	(188)	(714)	(382)	(892)	(759)	(930)	(882)
	Shareholders’ equity	—	154	235	164	502	842	657	462	485	631
Returns, %
Returns, %	ROA	(18.92)	(55.73)	(21.31)	(35.44)	(25.22)	4.48	(18.18)	(25.16)	(25.21)	(30.84)
	ROIC	0.00	0.00	0.00	0.00	0.00	7.34	0.00	0.00	0.00	0.00
	ROE	39.07	114.99	(61.00)	(42.48)	(36.93)	7.89	(35.62)	(54.87)	(59.77)	(63.26)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IDYA IDEAYA Biosciences, Inc.	$3.3B	— (loss-making)	— (loss-making)	+125.77% (above 0%: growing)	n/m	−41.09% (below 0%: shrinking)	100.00%	(1,380.73%)	Compare
CELC Celcuity, Inc.	$3.0B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
DNLI Denali Therapeutics Inc.	$2.9B	— (loss-making)	— (loss-making)	−89.74% (below 0%: shrinking)	n/m	−22.91% (below 0%: shrinking)	97.42%	(3,622.11%)	Compare
RCUS Arcus Biosciences, Inc.	$2.9B	— (loss-making)	— (loss-making)	−74.38% (below 0%: shrinking)	n/m	+10.53% (above 0%: growing)	100.00%	(234.15%)
ELVN Enliven Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
NRIX Nurix Therapeutics, Inc.	$2.7B	9.7×	— (loss-making)	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%	Compare
ZLAB Zai Lab Limited Unsponsored ADR	$2.7B	— (loss-making)	— (loss-making)	−3.33% (below 0%: shrinking)	n/m	−84.42% (below 0%: shrinking)	54.70%	(71.95%)	Compare
PGEN Precigen, Inc.	$2.6B	— (loss-making)	— (loss-making)	+6,322.66% (above 0%: growing)	n/m	+8.73% (above 0%: growing)	94.90%	41.18%	Compare
Median of peers	$2.9B	—	—	+125.77%	—	−30.99%	74.80%	0.00%

All 614 Biotechnology stocks →

Arcus Biosciences, Inc. (RCUS) key facts

Concern: Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
Concern: Arcus Biosciences, Inc. reported a net loss of $353.0 million, or a loss of $3.29 per share, for fiscal 2025.
Arcus Biosciences, Inc. (RCUS) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, RCUS traded at $22.12, a market capitalization of $2.9 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 23.8× sales.
Return on equity was −63.3% and debt-to-equity 0.22.
Its Piotroski F-score is 0 out of 9 and its Altman Z-score is 1.11 (distress zone) for fiscal 2025.